Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473503 | 0.82 | ADRA2A (0.40) | ALDH1A1HSD17B10MAP3K14ADRA2A | |
| SCHEMBL20449129 | 0.81 | ADRA2A (0.47) | MAP3K14ADRA2A | |
| SCHEMBL20449128 | 0.81 | ADRA2A (0.47) | MAP3K14ADRA2A | |
| SCHEMBL31372083 | 0.80 | HTR1A (0.42) | ALDH1A1TDP1 | |
| SCHEMBL20449102 | 0.78 | SCN9A (0.34) | MAP3K14 | |
| SCHEMBL20449103 | 0.78 | SCN9A (0.34) | MAP3K14 | |
| SCHEMBL20269757 | 0.78 | ALDH1A1 (0.31) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL13614278 | 0.78 | PDCD1 (0.34) | MAP3K14 | |
| SCHEMBL4350186 | 0.77 | SMN1; SMN2 (0.36) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL4350183 | 0.77 | SMN1; SMN2 (0.36) | ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | ALDH1A1 794/4885HSD17B10 3167/4885TDP1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.